The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are: * To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II * To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock. * The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug. * An ultrasound will be performed to look at blood flow through the kidney in the setting of vasodilatory shock. * A follow up phone call to check in with the patient will be performed 28 days after enrollment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Angiotensin-II will be given per the titration protocol.
Cohen Children's Medical Center of Northwell Health
New Hyde Park, New York, United States
Cohen Children's Medical Center
Queens, New York, United States
Percentage of patients who have improvement in mean arterial pressure or reduction in sum norepinephrine equivalent at Hour 2 after the start of Synthetic Angiotensin-II
Percentage (%) of patients who have improvement in mean arterial pressure (MAP, mmHg) or reduction in sum norepinephrine (NE) equivalent at Hour 2 after the start of Synthetic Angiotensin-II
Time frame: From enrollment to Hour 2
Change in MAP
Change in mean arterial pressure (mmHg) from baseline to 24 hours
Time frame: From enrollment to 24 hours
Change in systolic blood pressure
Change in systolic blood pressure (mmHg) from baseline to 24 hours
Time frame: From enrollment to 24 hours
Change in diastolic blood pressure
Change in diastolic blood pressure (mmHg) from baseline to 24 hours
Time frame: From enrollment to 24 hours
Change in concentration of serum lactate
Change in concentration of serum lactate (mmol/L) from baseline to 2 hours
Time frame: From enrollment to 24 hours
Change in pSOFA score
Change in pSOFA score from screening to 24 hours (%)
Time frame: From enrollment to 24 hours
Change in PRSIM-III score
Change in PRSIM-III score from screening to 24 hours (%)
Time frame: From enrollment to 24 hours
Change in total neutrophil count
Change in total neutrophil count (cells/µL) from the start of Synthetic Angiotensin-II to 24 hours
Time frame: From enrollment to 24 hours
Change in renal resistive index (%)
Change in renal resistive index (%) from the start of Synthetic Angiotensin-II to 24 hours after the start of Synthetic Angiotensin-II
Time frame: From enrollment to 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.